Track topics on Twitter Track topics that are important to you
Firstview Insight's Oral Mucositis Pipeline Review2019 provides an overview of the pipeline landscape of Oral Mucositis It provides comprehensive insights of all the clinical and nonclinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc.These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.
Oral mucositis is a common complication of cancer chemotherapy. It begins 510 days after the initiation of chemotherapy and lasts 714 days. Chemotherapyinduced oral mucositis causes the mucosal lining of the mouth to atrophy and break down, forming ulcers.Mucositis occurs when cancer treatments break down the rapidly divided epithelial cells lining the gastrointestinal tract which goes from the mouth to the anus, leaving the mucosal tissue open to ulceration and infection. Mucosal tissue, also known as mucosa or the mucous membrane, lines all body passages that communicate with the air, such as the respiratory and alimentary tracts, and have cells and associated glands that secrete mucus. The part of this lining that covers the mouth, called the oral mucosa, is one of the most sensitive parts of the body and is particularly vulnerable to chemotherapy and radiation. The oral cavity is the most common location for mucositis.
Oral mucositis is probably the most common, debilitating complication of cancer treatments, particularly chemotherapy and radiation. It can lead to several problems, including pain, nutritional problems as a result of inability to eat, and increased risk of infection due to open sores in the mucosa. It has a significant effect on the patient's quality of life and can be doselimiting i.e., requiring a reduction in subsequent chemotherapy doses.
Signs of Mucositis
Signs and symptoms of mucositis include:
Red, shiny, or swollen mouth and gums
Blood in the mouth
Sores in the mouth or on the gums or tongue
Soreness or pain in the mouth or throat
Difficulty swallowing or talking
Feeling of dryness, mild burning, or pain when eating food
Soft, whitish patches or pus in the mouth or on the tongue
Increased mucus or thicker saliva in the mouth
An extreme case of the condition is called confluent mucositis. In a worst case, the mucous membrane of the patient's entire mouth and tongue can be coated by a white mucus coating that is up to a millimeter thick. The combination of mucus, excess saliva and pain can make it difficult or even impossible to treat.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and preclinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
The report provides a competitive landscape
The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and endpoint status
The report provides the list of companies which are the most active in the pipeline
The report covers pipeline products based on various stages of development ranging from preregistration till discovery
The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action MoA; route of administration RoA; Stage of development; clinical trial status; licensing and collaboration details other developmental activities
The report features comparative analysis of product profiles based on molecule type; mechanism of action MoA; route of administration RoA
The report summarizes all the dormant and discontinued pipeline projects
The report also provides latest news for the past one year
Reasons To Buy
To identifying prominent players in the treatment landscape
To determine the drivers; barriers and unmet need in the treatment space
Gain strategically significant competitor information; analysis; and insights to formulate effective RD strategies
Define inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration
List of products
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...